Our Cellular Regeneration platform uses viral vectors to deliver genes to specific cells in the heart to regenerate cardiomyocytes in vivo. The product candidates arising from this platform are intended to overcome the shortcomings of traditional therapies that are not able to address the loss of cardiomyocytes. We believe this platform has the potential for broad utility across a range of heart conditions that result in the loss of cardiomyocytes, including myocardial infarction, chemotherapy-related toxicity, and viral infection.
Our Gene Therapy platform uses AAVs to deliver genes to specific cells in the heart to correct or compensate for functional defects. We have the ability to use both known AAV capsids as well as novel capsids identified through our internal capsid engineering capabilities to target cardiomyocytes, cardiac fibroblasts or other cells important to the proper functioning of the heart. The product candidates arising from this platform are intended to overcome the shortcomings of traditional therapies that are not able to address the underlying problems that contribute to heart disease. We believe this platform has potentially broad utility for both genetic and non-genetic forms of heart disease.
Our Precision Medicine platform uses human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) as proprietary disease models and analysis of human genetics for the identification of new targets, validation of known targets, and high-throughput screening for drug discovery. This platform is intended to overcome the shortcomings of traditional drug development efforts that rely more heavily on efficacy in animal models to develop therapies intended for human heart disease. We believe this platform has potentially broad utility for the identification of targets and therapies in a modality-agnostic manner—including gene therapy, small molecules, and biologics—for both genetic and non-genetic forms of heart disease.
Tenaya’s mission is to discover, develop, and deliver therapies that address the underlying drivers of heart disease. We were founded by leading cardiovascular scientists from, and have established academic collaborations with, Gladstone Institutes and University of Texas Southwestern Medical Center, and have forged additional partnerships aimed at helping advance our groundbreaking therapies. We are always open to strategic collaborations to push new boundaries in the treatment of heart disease.
For partnering inquiries, please contact us at firstname.lastname@example.org.